Stock, pipeline and biotech catalyst intelligence
Reported statements
| USD | 2026 |
|---|---|
| Revenue | — |
| R&D expense | $12.8M |
| Operating income | −$18.8M |
| Net income | −$17.8M |
| Cash & equivalents | $118.0M |
| Total debt | — |
| Operating cash flow | −$14.2M |
| Free cash flow | −$14.2M |
Company profile
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.